PTCT Q4 2025 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$165M-22.7% YoY

Gross Profit

$148M90.1% margin

Operating Income

-$82M-49.6% margin

Net Income

-$135M-82.0% margin

EPS (Diluted)

$-1.67

QoQ Revenue Growth

-22.0%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$37M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$3.1B

Stockholders' Equity

-$205M

Cash & Equivalents

$985M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165M	$213M	-22.7%
Gross Profit	$148M	$197M	-24.6%
Operating Income	-$82M	-$162M	+49.7%
Net Income	-$135M	-$66M	-104.8%

Revenue Segments

Product

$184M70%

Royalty

$79M30%

Geographic Segments

Non-US

$178M53%

UNITED STATES

$159M47%